Answers are grounded in this paper and cite their sources.
BACKGROUND: The roles and responsibilities of transplant pharmacists (TxPharms) continue to evolve. The aim of this survey was to obtain responses from individuals who identify as United States TxPharms and compare results with a similar 2013 survey. METHODS: Initial survey dissemination occurred electronically to American Society of Transplantation Pharmacy Community of Practice (AST TxPharm COP) and American College of Clinical Pharmacy (ACCP) Transplant Practice Research Network (PRN) members. RESULTS: Between November 2023 and May 2024, 173 TxPharms responded representing 102/249 of U.S. accredited transplant centers compared with 176 respondents representing 113/278 centers in 2013, at survey response time. The 2023 survey found that core competencies continue to expand in providing direct patient care across all phases of transplant and living donation care and organ types. Staffing limitations and payor/formulary/medication access issues were the most common practice barriers reported. The average job satisfaction rating was 71% (where 0% is not satisfied at all to 100% completely satisfied). When asked how likely in the next 12 months one was to leave clinical practice, 32% answered yes or maybe. In 2023, 93% (95/102) of centers reported full-time equivalent (FTE) numbers. The TxPharm FTEs per 100 cases based on total number of transplants performed per transplant center median (range) estimates showed little change between 2013 and 2023 (1.5 [0-21.4] vs. 1.4 [0.1-7.1]), despite significant increases in waitlisted patients, transplantation volumes, and expansion of ambulatory services compared with 2013. CONCLUSION: Despite substantial growth in U.S. waitlist and solid organ transplant volumes over the past decade, TxPharm FTEs per 100 transplants showed little change between 2013 and 2023. Most TxPharms are satisfied with their jobs and responsibilities, but challenges include high workloads and workforce attrition. These findings highlight a widening mismatch between transplant activity and the available TxPharm workforce.
No takes yet. Share an insight, caveat, or question.
Kaiser et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: